New Delhi, 14th July, 23- CŌRE Diagnostics, a leading player in the health and diagnostics industry, is proud to announce its collaboration with PredOmix Technologies Pvt. Ltd. to launch OncoVeryx-F, a ground-breaking multi-cancer detection test specifically designed for high-risk and asymptomatic women.
CŌRE Diagnostics is a Clinical Data Science company with a Center-of-Excellence in High End Diagnostics built in. They are focused on bringing the most advanced testing techniques and expertise to India. Dinesh Chauhan, who is the CEO and is at the helm of affairs at CŌRE is a seasoned industry veteran with 25 years of rich experience in the Diagnostics Industry.
PredOmix Technologies Pvt. Ltd., founded in 2018, is an innovation-driven company specialising in health tech solutions. Their expertise lies in integrating multi-dimensional approaches and harnessing the power of deep learning to develop cutting-edge technologies in preventive healthcare and early-stage disease diagnosis. Dr Kanury V S Rao, a highly accomplished expert in immunology, cell and molecular biology, and infectious disease biology, is the Co-Founder and Chief Scientific Officer at PredOmix.
Early-stage cancer detection is critical in improving treatment outcomes and saving lives, and OncoVeryx-F is set to revolutionise early-stage cancer detection and improve treatment outcomes. OncoVeryx-F’s ability to identify cancer at Stages 1 and 2 increases the likelihood of successful treatment, providing patients a better chance of recovery. With an impressive accuracy rate of 98%, OncoVeryx-F can detect the presence or absence of cancer and accurately identify the Tissue of Origin (TOO) in a single test. This breakthrough technology offers a comprehensive screening solution for four cancers, including breast, endometrial, cervical, and ovarian cancer.
By offering a highly accurate and non-invasive screening tool, OncoVeryx-F aims to empower women and their healthcare providers to take proactive steps towards early intervention and personalised treatment plans.
“We are thrilled to collaborate with PredOmix Technologies Pvt. Ltd. to bring OncoVeryx-F to the market,” said Mr Dinesh Chauhan, CEO of CŌRE Diagnostics. “This ground-breaking multi-cancer detection test represents a significant advancement in early-stage cancer diagnosis. By combining the expertise of PredOmix with our commitment to improving patient outcomes, we aim to make a tangible difference in the lives of women at high risk for cancer.”
PredOmix’s Dr. Kanury Rao, says early cancer detection is what saves lives. “OncoVeryx-F is a simple blood test that looks for cancer metabolic signatures in the bloodstream” Dr. Rao says. “This test is very significant for women. We have developed this test for early detection, so we can diagnose cancer earlier and so treatment can begin earlier and avoid some of the long-term problems and help women live longer. Together with CŌRE Diagnostics, we aim to reduce the number of advanced cancers in the country”.
A milestone in the fight against cancer, this collaboration between CŌRE Diagnostics and PredOmix Technologies Pvt. Ltd. signifies a shared commitment to leveraging advanced technologies to enhance preventive healthcare and early-stage disease diagnosis.
